These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25245932)

  • 41. The clinical characteristics of juvenile-onset systemic sclerosis in Japanese patients.
    Hatta Y; Hasegawa M; Matsushita T; Hamaguchi Y; Fujimoto M; Takehara K
    Mod Rheumatol; 2014 Mar; 24(2):377-9. PubMed ID: 24593219
    [No Abstract]   [Full Text] [Related]  

  • 42. T-cell lymphopenia associated with infliximab and cyclophosphamide.
    Wachi K; Prasertsuntarasai T; Kishimoto M; Uramoto K
    Am J Med Sci; 2005 Jul; 330(1):48-51. PubMed ID: 16020999
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thymoglobulin and cyclophosphamide as treatment for diffuse cutaneous systemic sclerosis.
    Holmberg LA; Furst DE; McSweeney PA; Nash RA
    J Rheumatol; 2009 Aug; 36(8):1839. PubMed ID: 19671826
    [No Abstract]   [Full Text] [Related]  

  • 44. Haemopoietic stem-cell transplantation for systemic sclerosis.
    Sullivan KM; Wigley FM; Denton CP; van Laar JM; Furst DE
    Lancet; 2012 Jan; 379(9812):219; author reply 219-20. PubMed ID: 22265628
    [No Abstract]   [Full Text] [Related]  

  • 45. Systemic sclerosis.
    Hughes M; Herrick A
    Br J Hosp Med (Lond); 2012 Sep; 73(9):509-10, 511-6. PubMed ID: 23124403
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute limb ischemia in an adolescent with COVID-19 and systemic scleroderma: a case report.
    Milan MJDC; Dans LF; Torres-Ticzon VMF
    BMC Pediatr; 2022 Dec; 22(1):737. PubMed ID: 36577976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic interventions in systemic sclerosis.
    van den Hoogen FH
    Neth J Med; 1998 Sep; 53(3):137-8. PubMed ID: 9803147
    [No Abstract]   [Full Text] [Related]  

  • 48. Recent advances in the management of juvenile systemic sclerosis.
    Zulian F; Balzarin M; Birolo C
    Expert Rev Clin Immunol; 2017 Apr; 13(4):361-369. PubMed ID: 27690679
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-inflammatory: new trends in the treatment of the patient with systemic sclerosis.
    Valentini G; Cerinic MM
    Expert Opin Emerg Drugs; 2008 Jun; 13(2):227-36. PubMed ID: 18537518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of monthly cyclophosphamide pulses on skin sclerosis in systemic sclerosis.
    Khader A; Valiaveetil B; Nalini SD; George B; Sasidharanpillai S; Nazeer MMA; Manikath N
    Indian J Dermatol Venereol Leprol; 2021; 87(5):728-731. PubMed ID: 34379952
    [No Abstract]   [Full Text] [Related]  

  • 51. [Systemic sclerosis: Efficacy of intravenous immunoglobulins in severe cardiac involvement?].
    Cacciatore C; Riviere S; Cohen A; Gatfosse M; Ederhy S; Fain O; Mekinian A
    Rev Med Interne; 2018 Jul; 39(7):594-596. PubMed ID: 29415815
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Difficult-to-diagnose diabetes in a patient treated with cyclophosphamide - the contradictory roles of immunosuppressant agents: a case report.
    García-Sáenz M; Uribe-Cortés D; Ramírez-Rentería C; Ferreira-Hermosillo A
    J Med Case Rep; 2018 Dec; 12(1):364. PubMed ID: 30526658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma).
    Tolchin SF; Winkelstein A; Rodnan GP; Pan SF; Nankin HR
    Arthritis Rheum; 1974; 17(4):375-82. PubMed ID: 4851019
    [No Abstract]   [Full Text] [Related]  

  • 54. Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center.
    Bruni C; Praino E; Guiducci S; Bellando-Randone S; Furst DE; Matucci-Cerinic M
    Joint Bone Spine; 2017 Dec; 84(6):747-748. PubMed ID: 27932280
    [No Abstract]   [Full Text] [Related]  

  • 55. Management of juvenile-onset systemic sclerosis with systemic immunosuppressive therapies: An evidence-based review.
    Abduelmula A; Rankin BD; Luca NJ; Prajapati VH
    J Am Acad Dermatol; 2023 Jan; 88(1):234-236. PubMed ID: 35569591
    [No Abstract]   [Full Text] [Related]  

  • 56. Systemic sclerosis with portal hypertensive ascites responded to corticosteroid treatment.
    Leng XM; Sun XF; Zhang X; Zhang W; Li MT; Zeng XF
    Chin Med J (Engl); 2012 Jul; 125(13):2390-2. PubMed ID: 22882868
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Problems to Consider Before Determining the Regimen of the Treatment for Juvenile Systemic Sclerosis Treatment: A Case Report Where Tocilizumab Monotherapy Succeeded Efficiently and Safely.
    Funauchi M; Kinoshita K
    Clin Med Insights Arthritis Musculoskelet Disord; 2022; 15():11795441211066307. PubMed ID: 35250323
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Are we too lenient with immunosuppression in severe cases of Systemic Sclerosis?
    Siegert E; Riemekasten G
    Rheumatology (Oxford); 2016 Oct; 55(10):1914-6. PubMed ID: 27330162
    [No Abstract]   [Full Text] [Related]  

  • 59. Update on juvenile systemic sclerosis.
    Foeldvari I
    Curr Rheumatol Rep; 2015 Mar; 17(3):18. PubMed ID: 25761925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis.
    Mayes MD
    Curr Rheumatol Rep; 2000 Dec; 2(6):512-6. PubMed ID: 11123106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.